ArticleFrontiers in cardiovascular medicine2025
Retrograde transarterial closure of small aneurysmal perimembranous ventricular septal defects using the amplatzer duct occluder II: a single-center mid-term analysis.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter closure of aneurysmal perimembranous ventricular septal defects (pmVSDs) presents distinct anatomical challenges. While the retrograde transarterial approach using the Amplatzer Duct Occluder II (ADO II) has been described, data focusing on mid-term outcomes in this specific patient population remain limited. Methods: We conducted a single-center, retrospective analysis of pediatric patients with hemodynamically significant small aneurysmal pmVSDs who underwent transcatheter closure via a retrograde approach with the ADO II device. Primary endpoints included procedural success, complications, and mid-term clinical and echocardiographic outcomes. Results: Twenty-seven patients (median age 3.6 [3.0-4.6] years; median weight 15.9 [14.1-17.5] kg) were included. Defects had a median left ventricular inlet diameter of 4.0 [3.2-4.5] mm and right ventricular outlet diameter of 2.7 [2.5-3.1] mm; 59.3% were saccular aneurysms. The procedure was successful in 100% of cases using ADO II devices ranging from 4-4 to 6-6 mm. Median fluoroscopy time was 8.6 [8.1-12.1] min. No major procedural complications occurred. The immediate complete closure rate was 85.2%, rising to 100% at a median follow-up of 49 [28-72] months, with resolution of all clinical symptoms and no late device-related adverse events. Conclusion: Retrograde transarterial closure of small aneurysmal pmVSDs with the ADO II device is a feasible, safe, and effective therapeutic strategy in appropriately selected pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.